EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Immune Complexes Shape the Pathogenicity of Autoantibodies in Systemic Autoimmune Diseases: Insights From an FcγRIIIA ‐Reporter Assay

Koji Suzuki iD, Masaru Takeshita iD, Yuki Imai, Hiroyuki Fukui, Kazunori Furuhashi, Kotaro Matsumoto iD, Jun Kikuchi iD, Keiko Yoshimoto, Yuko Kaneko iD

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.70159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Koji Suzuki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Receptors, IgG, Autoantibodies, Autoimmune Diseases, Antigen-Antibody Complex. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research, Keio University Academic Development Funds, Kowa Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Immune complexes (ICs), formed by autoantigen and autoantibody, play a pathogenic role in systemic autoimmune diseases through stimulation of Fcγ receptors (FcγR). However, studies investigating bioactivity of circulating ICs across various diseases remain limited. We aimed to quantify bioactivity of serum ICs using an FcγR‐reporter cell assay and examine their association with disease activity.

Methods

We assessed the bioactivity of serum ICs using the FcγRIIIA‐reporter assay. Serum samples were obtained from healthy controls (n = 56), infectious disease controls (n = 12), systemic lupus erythematosus (SLE) (n = 175), Sjögren disease (n = 71), mixed connective tissue disease (n = 22), idiopathic inflammatory myopathies (n = 73), systemic sclerosis (n = 107), and rheumatoid arthritis (n = 51).

Results

The bioactivity of ICs was significantly elevated across various systemic autoimmune diseases and associated with disease activity. In SLE, bioactivity of ICs was notably elevated compared with other diseases. The bioactivity in patients with SLE reflected disease activity with sensitivity of 81% and specificity of 69%. In patients with low anti–double‐stranded DNA antibody levels, those with high IC bioactivity were at higher risk of clinical symptoms including nephritis, arthritis, and skin involvement, providing additive value in assessing SLE activity. Longitudinal analysis also showed that the FcγRIIIA‐reporter assay more sensitively reflected flares than conventional serological markers, and those who achieved a low FcγRIIIA‐reporter response within the initial 3 months tended to achieve remission at 24 months (90% vs 75%, P = 0.56).

Conclusions

The FcγRIIIA‐reporter assay enables precise quantification of pathogenic bioactivity of ICs in various systemic autoimmune diseases, providing complementary information to existing serological markers. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, IgGAutoantibodiesAutoimmune DiseasesAntigen-Antibody ComplexHumansFemaleLupus Erythematosus, SystemicScleroderma, SystemicArthritis, RheumatoidAdultMaleMiddle AgedMyositisSjogren's SyndromeCase-Control StudiesAged

Substanzen

Receptors, IgGAutoantibodiesAntigen-Antibody ComplexFCGR3A protein, human

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

ORCID-Profile: Koji Suzuki, Masaru Takeshita, Kotaro Matsumoto, Jun Kikuchi, Yuko Kaneko

Förderung

  • Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research
  • Keio University Academic Development Funds
  • Kowa Company
  • Program for the Advancement of Next Generation Research Projects, Japan Society for the Promotion of Science (JSPS) KAKENHI
  • Keio University Ushioda Memorial Doctoral Student Grant
  • Japan Society for the Promotion of Science

Zitieren

APA

Suzuki, K., Takeshita, M., Imai, Y., Fukui, H., Furuhashi, K., Matsumoto, K., Kikuchi, J., Yoshimoto, K., & Kaneko, Y. (2026). Immune Complexes Shape the Pathogenicity of Autoantibodies in Systemic Autoimmune Diseases: Insights From an FcγRIIIA ‐Reporter Assay. Arthritis & Rheumatology. https://doi.org/10.1002/art.70159

Vancouver

Suzuki K, Takeshita M, Imai Y, Fukui H, Furuhashi K, Matsumoto K, et al. Immune Complexes Shape the Pathogenicity of Autoantibodies in Systemic Autoimmune Diseases: Insights From an FcγRIIIA ‐Reporter Assay. Arthritis & Rheumatology. 2026. doi:10.1002/art.70159

BibTeX
@article{Suzuki2026,
  author = {Suzuki, Koji and Takeshita, Masaru and Imai, Yuki and Fukui, Hiroyuki and Furuhashi, Kazunori and Matsumoto, Kotaro and Kikuchi, Jun and Yoshimoto, Keiko and Kaneko, Yuko},
  title = {Immune Complexes Shape the Pathogenicity of Autoantibodies in Systemic Autoimmune Diseases: Insights From an FcγRIIIA ‐Reporter Assay},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70159}
}
Kostenlos starten →